Clinical trials for Lung cancer
276 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
1 recruiting site
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
1
Targeted therapy
Systemic Treatment-Naive
1 recruiting site
Janssen
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
KRAS G12C
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Lung cancer
#NCT07222566
#2025-523461-17-01
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Non-squamous NSCLC
Locally Advanced
Metastatic
None
Systemic Treatment-Naive
ALK
BRAF
EGFR
MET
NTRK-1/2/3
RET
ROS-1
Immunotherapy
Targeted therapy
1 recruiting site
Pfizer
Phase 3
Lung cancer
#NCT06692738
#2024-514281-39-00
NSCLC (Non-Small Cell Lung Cancer)
Squamous NSCLC
Metastatic
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
Immunotherapy
8 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT06350097
#2023-509883-89-00
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 3
Lung cancer
#NCT07195695
#2025-521284-12-00
NSCLC (Non-Small Cell Lung Cancer)
Localized
HER2
None
Systemic Treatment-Naive
ALK
EGFR
Radiotherapy
5 recruiting sites
Boehringer Ingelheim
Phase 3
Lung cancer
#NCT05918302
#2022-502154-13-00
Neuroendocrine tumor/carcinoma other than SCLC
Neuroendocrine tumor/carcinoid
Locally Advanced
Metastatic
None
1
2
8 recruiting sites
Grupo Espanol de Tumores Neuroendocrinos